Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB1 | P08183 | 1/20 | 0.52 |
| ▸ | AGTR2 | P50052 | 6/20 | 0.52 |
| ▸ | KLK7 | P49862 | 1/20 | 0.48 |
| ▸ | MCL1 | Q07820 | 5/20 | 0.45 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.44 |
| ▸ | BDKRB2 | P30411 | 2/20 | 0.43 |
| ▸ | JAK2 | O60674 | 1/20 | 0.43 |
| ▸ | JAK1 | P23458 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL376159 | 1.00 | ABCB1 (0.52) | ABCB1AGTR2KLK7MCL1UCHL1 | |
| SCHEMBL3179881 | 1.00 | ABCB1 (0.52) | ABCB1AGTR2KLK7MCL1UCHL1 | |
| SCHEMBL708630 | 1.00 | ABCB1 (0.52) | ABCB1AGTR2KLK7MCL1UCHL1 | |
| SCHEMBL708629 | 1.00 | ABCB1 (0.52) | ABCB1AGTR2KLK7MCL1UCHL1 | |
| SCHEMBL7287734 | 1.00 | ABCB1 (0.52) | ABCB1AGTR2KLK7MCL1UCHL1 | |
| SCHEMBL1448119 | 1.00 | ABCB1 (0.52) | ABCB1AGTR2KLK7MCL1UCHL1 | |
| SCHEMBL708628 | 1.00 | ABCB1 (0.52) | ABCB1AGTR2KLK7MCL1UCHL1 | |
| SCHEMBL26604823 | 1.00 | ABCB1 (0.52) | ABCB1AGTR2KLK7MCL1UCHL1 | |
| SCHEMBL13164545 | 0.95 | ABCB1 (0.47) | ABCB1AGTR2KLK7MCL1UCHL1 | |
| SCHEMBL29548192 | 0.93 | MCL1 (0.50) | ABCB1AGTR2KLK7MCL1UCHL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120238749-A1 | INHIBITORS OF INTERLEUKIN-1 BETA CONVERTING ENZYME | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-09-20 | — | — | US | disclosed |
| WO-2011007877-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE EPOXY COMPOUND, LIGAND USED IN THE METHOD, COMPLEX, METHOD FOR PRODUCING THE LIGAND, AND METHOD FOR PRODUCING THE COMPLEX | 日産化学工業株式会社 (JP) | 2011-01-20 | — | — | WO | disclosed |
| US-20110015371-A1 | Inhibitors of interleukin-1 beta converting enzyme | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-01-20 | — | — | US | disclosed |
| US-7772366-B2 | Inhibitors of interleukin-1β converting enzyme | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-08-10 | — | — | US | disclosed |
| EP-2123665-A2 | Inhibitors of interleukin-1Beta converting enzyme | Vertex Pharmaceuticals Incorporated (US) | 2009-11-25 | — | — | EP | disclosed |
| US-20080070953-A1 | Inhibitors of interleukin-1 beta converting enzyme | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-03-20 | — | — | US | disclosed |
| US-7288624-B2 | Inhibitors of interleukin-1β converting enzyme | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-10-30 | — | — | US | disclosed |
| EP-1394175-A1 | Inhibitors of interleukin-1beta converting enzyme | Vertex Pharmaceuticals Incorporated (US) | 2004-03-03 | — | — | EP | disclosed |
| EP-1155013-B1 | HETEROCYCLIC BENZENESULPHONAMIDE COMPOUNDS AS BRADYKININE ANTAGONISTS | FOURNIER IND & SANTE (FR) | 2003-07-23 | — | — | EP | disclosed |
| US-6479515-B1 | FOR THE TREATMENT OF PAIN AND INFLAMMATION, AND ESPECIALLY IN THE TREATMENT OF ASTHMA, CEREBRAL TRAUMATIC SHOCK AND ALLERGIC RHINITIS | FOURNIER INDUSTRIE ET SANTE (FR) | 2002-11-12 | — | — | US | disclosed |
| EP-0784628-A1 | INHIBITORS OF INTERLEUKIN-1$g(b) CONVERTING ENZYME | Vertex Pharmaceuticals Incorporated (US) | 1997-07-23 | — | — | EP | disclosed |
| EP-0729472-A4 | PIPERIDINYLCAMPHORSULFONYL OXYTOCIN ANTAGONISTS | MERCK & CO INC (US) | 1997-03-19 | — | — | EP | disclosed |
| EP-0729472-A1 | PIPERIDINYLCAMPHORSULFONYL OXYTOCIN ANTAGONISTS | MERCK & CO. INC. (US) | 1996-09-04 | — | — | EP | disclosed |
| WO-1995035308-A1 | INHIBITORS OF INTERLEUKIN-1β CONVERTING ENZYME | VERTEX PHARMACEUTICALS INCORPORATED (US) | 1995-12-28 | — | — | WO | disclosed |
| WO-1995014025-A1 | PIPERIDINYLCAMPHORSULFONYL OXYTOCIN ANTAGONISTS | MERCK & CO., INC. (US) | 1995-05-26 | — | — | WO | disclosed |
| EP-0572365-A2 | Heteroprostanoids, process for their production and therapeutical use thereof | NUOVO CONSORZIO SANITARIO NAZIONALE del Dott. Paolo Malizia & C. - S.A.S. (IT) | 1993-12-01 | — | — | EP | disclosed |
| US-5229363-A | Fungicides | MERCK & CO., INC. (US) | 1993-07-20 | — | — | US | disclosed |
| EP-0500170-A2 | Cyclic hexapeptides having antibiotic activity | MERCK & CO. INC. (US) | 1992-08-26 | — | — | EP | disclosed |
| EP-0486280-A2 | Piperidinylcamphorsulfonyl oxytocin antagonists | MERCK & CO. INC. (US) | 1992-05-20 | — | — | EP | disclosed |
| EP-0115091-A1 | N-carboxyacyl derivatives of cyclic amino acids, useful as antihypertensives | ENI-Ente Nazionale Idrocarburi (IT) | 1984-08-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080070953-A1 | Inhibitors of interleukin-1 beta converting enzyme | IL1B, IL1A, IL1R1 | ABCB1 1930/4885AGTR2 647/4885KLK7 922/4885 |
| US-20110015371-A1 | Inhibitors of interleukin-1 beta converting enzyme | IL1B, IL1A, IL1R1 | ABCB1 1930/4885AGTR2 647/4885KLK7 922/4885 |
| US-20120238749-A1 | INHIBITORS OF INTERLEUKIN-1 BETA CONVERTING ENZYME | IL1B, IL1A, IL1R1 | ABCB1 1930/4885AGTR2 647/4885KLK7 922/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.